Evidence map›Paper›PMID 37732274›Full record

ArticlebioRxiv : the preprint server for biology2023

The Fanconi anemia core complex promotes CtIP-dependent end-resection to drive homologous recombination at DNA double-strand breaks.

Bert van de Kooij, Fenna J van der Wal, Magdalena B Rother, Pau Creixell, Merula Stout, Wouter Wiegant, Brian A Joughin, Julia Vornberger, Marcel A T M van Vugt, Matthias Altmeyer and 2 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 6 countries.

Bert van de KooijDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Fenna J van der WalDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Magdalena B RotherDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Pau CreixellKoch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Merula StoutDepartment of Molecular Mechanisms of Disease, University of Zurich (UZH), Zurich, Switzerland.
Wouter WiegantDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Brian A JoughinKoch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Julia VornbergerDepartment of Molecular Mechanisms of Disease, University of Zurich (UZH), Zurich, Switzerland.
Marcel A T M van VugtDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, the Netherlands.
Matthias AltmeyerDepartment of Molecular Mechanisms of Disease, University of Zurich (UZH), Zurich, Switzerland.
Michael B YaffeKoch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Haico van AttikumDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Leiden University Medical Center · NLUniversity of Zurich · CHUniversity Medical Center Groningen · NLHadassah Medical Center · ILMassachusetts Institute of Technology · USUniversity of Cambridge · GB

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6M
Protein Kinase Signaling and Cell Cycle ControlR01ES015339 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2007 to 2017
$4.3M
Protein Kinase Signaling in the Genotoxic Stress ResponseR35ES028374 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2017 to 2024
$3.9M
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7M
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA226898NIEHS NIH HHS P30 ES002109NIEHS NIH HHS R01 ES015339NIEHS NIH HHS R35 ES028374
6 · The paper itself

Abstract

Homologous Recombination (HR) is a high-fidelity repair mechanism of DNA Double-Strand Breaks (DSBs), which are induced by irradiation, genotoxic chemicals or physiological DNA damaging processes. DSBs are also generated as intermediates during the repair of interstrand crosslinks (ICLs). In this context, the Fanconi anemia (FA) core complex, which is effectively recruited to ICLs, promotes HR-mediated DSB-repair. However, whether the FA core complex also promotes HR at ICL-independent DSBs remains controversial. Here, we identified the FA core complex members FANCL and Ube2T as HR-promoting factors in a CRISPR/Cas9-based screen with cells carrying the DSB-repair reporter DSB-Spectrum. Using isogenic cell-line models, we validated the HR-function of FANCL and Ube2T, and demonstrated a similar function for their ubiquitination-substrate FANCD2. We further show that FANCL and Ube2T are directly recruited to DSBs and are required for the accumulation of FANCD2 at these break sites. Mechanistically, we demonstrate that FANCL ubiquitin ligase activity is required for the accumulation of the nuclease CtIP at DSBs, and consequently for optimal end-resection and Rad51 loading. CtIP overexpression rescues HR in FANCL-deficient cells, validating that FANCL primarily regulates HR by promoting CtIP recruitment. Together, these data demonstrate that the FA core complex and FANCD2 have a dual genome maintenance function by promoting repair of DSBs as well as the repair of ICLs.

Identifiers

PMID37732274
PMCPMC10508776
OpenAlexW4386484436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.